Bright Minds Biosciences Inc. Common Stock
DRUGStock
$74.23−74.81%52W
Market Cap$743.59M
P/E—
Div yield—
Beta2.27
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-19.78%
Price vs S&P 500 (4W)21.61%
VGM Score45.25
Market Capitalization$743.59M
Analyst Recommendations
Jul 2022
Aug 2022
Sep 2022
Oct 2022
4.29
4.29
4.29
4.29
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
DRUGBright Minds Biosciences Inc. Common Stock | — | — | C | $74.23 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Bright Minds Biosciences develops next-generation serotonin agonists targeting treatment-resistant neuropsychiatric and pain disorders, including depression, PTSD, epilepsy, and chronic pain. The company's approach combines the therapeutic benefits of psychedelic and serotonergic compounds while reducing side effects compared to first-generation treatments. By addressing underlying neurocircuit abnormalities, Bright Minds targets large patient populations with significant unmet medical needs.